Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Abstract EN

Advanced glycation end products (AGEs) may induce cardiac remodeling in kidney disease by promoting fibroblast growth factor 23 (FGF-23) expression.

Since AGEs are increased in diabetes mellitus (DM), our first aim was to evaluate the existence of any potential association between AGEs, FGF-23, inflammation, and increased cardiovascular risk in DM patients on dialysis (CKD-G5D).

Secondarily, we explored the potential role of the soluble receptor for AGEs (sRAGE) as a marker of heart failure.

Levels of glycated albumin (GA), sRAGE, c-terminal FGF-23 (cFGF-23), brain natriuretic peptide (BNP), and inflammatory mediators were compared between DM and non-DM CKD-G5D patients.

The levels of sRAGE, cFGF-23, BNP, and proinflammatory markers were over the ranges of normality in both DM and non-DM groups.

Only GA and sRAGE levels were increased in DM compared to non-DM patients.

Plasma levels of sRAGE and CRP were the only independent predictors of BNP concentration.

In conclusion, in DM CKD-G5D patients, sRAGE appeared to be a marker of cardiac remodeling.

Indeed, its increase could be a potential protective mechanism against the increased risk of cardiovascular complications related to AGEs and inflammation.

The causal relationship between sRAGE and cardiovascular risk in these patients needs to be further confirmed by mechanistic studies.